Pre-market hot trades in US stocks: Oriental Rise pre-market down 10.10%; TTM Tech pre-market up 9.93%

Oriental Rise pre-market down 10.10%; TTM Tech pre-market up 9.93%; PicoCELA pre-market up 222.22%; Akari Therapeutics pre-market up 97.08%; MetaVia pre-market up 87.49%

Pre-market Hot Trades in US Stocks

Oriental Rise is down 10.10% in pre-market trading. There have been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

TTM Tech is up 9.93% in pre-market trading. Based on recent key news:

On May 19, TTM Tech expects revenue to reach $4 billion in 2026, a year-on-year increase of approximately 38%. The company's CEO stated in an interview with the Orange County Business Journal that the growth trend in the first half of 2026 is expected to continue into the second half, and this optimistic financial outlook has driven the stock price up. Source: SEC announcement
On May 18, TTM Tech detailed its 2026 financial outlook in documents submitted to the SEC, further enhancing investor confidence. Source: SEC announcement. The technology industry is experiencing strong growth, with clear capital inflows.

Top Gainers in Pre-market US Stocks

PicoCELA is up 222.22% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Akari Therapeutics is up 97.08% in pre-market trading. Based on recent key news:

On May 21, Akari Therapeutics announced the completion of a $5 million private placement, significantly boosting the stock price. This move enhances the company's financial strength and attracts investor attention.
On May 22, Akari Therapeutics announced the synergistic effects of its newly developed ADC and KRAS inhibitor combination in pancreatic cancer models, showing potential treatment strategies for KRAS-driven cancers, further boosting market confidence.
On May 19, Akari Therapeutics disclosed its ongoing virtual manufacturing strategy in documents released by the SEC, relying on CDMO for development and clinical supply, showcasing the company's innovation in operational models. The biotechnology industry has been active recently, with clear capital inflows.

MetaVia is up 87.49% in pre-market trading. Based on recent key news:

On May 20, MetaVia Inc. released a new product announcement, significantly boosting the stock price. The company published this news through PR Newswire, and the market reacted positively, with the stock price rising 87.49% in pre-market trading;
On May 22, MetaVia's stock price fell 3.63% during the trading session, mainly due to technical indicators showing overbought conditions. According to data from Benzinga Pro, the RSI reached 80.57, indicating that the stock price may face correction pressure;
There have been no other significant news recently. Technical indicators show overbought conditions, and attention should be paid to correction risks

Pre-market Hot Trades in US Stocks

TTM Tech is up 9.93% in pre-market trading. Based on recent key news:

On May 19, TTM Tech expects revenue to reach $4 billion in 2026, a year-on-year increase of approximately 38%. The company's CEO stated in an interview with the Orange County Business Journal that the growth trend in the first half of 2026 is expected to continue into the second half, and this optimistic financial outlook has driven the stock price up. Source: SEC announcement
On May 18, TTM Tech detailed its 2026 financial outlook in documents submitted to the SEC, further enhancing investor confidence. Source: SEC announcement. The technology industry is experiencing strong growth, with clear capital inflows.

Top Gainers in Pre-market US Stocks

Akari Therapeutics is up 97.08% in pre-market trading. Based on recent key news:

On May 21, Akari Therapeutics announced the completion of a $5 million private placement, significantly boosting the stock price. This move enhances the company's financial strength and attracts investor attention.
On May 22, Akari Therapeutics announced the synergistic effects of its newly developed ADC and KRAS inhibitor combination in pancreatic cancer models, showing potential treatment strategies for KRAS-driven cancers, further boosting market confidence.
On May 19, Akari Therapeutics disclosed its ongoing virtual manufacturing strategy in documents released by the SEC, relying on CDMO for development and clinical supply, showcasing the company's innovation in operational models. The biotechnology industry has been active recently, with clear capital inflows.

MetaVia is up 87.49% in pre-market trading. Based on recent key news:

On May 20, MetaVia Inc. released a new product announcement, significantly boosting the stock price. The company published this news through PR Newswire, and the market reacted positively, with the stock price rising 87.49% in pre-market trading;
On May 22, MetaVia's stock price fell 3.63% during the trading session, mainly due to technical indicators showing overbought conditions. According to data from Benzinga Pro, the RSI reached 80.57, indicating that the stock price may face correction pressure;
There have been no other significant news recently. Technical indicators show overbought conditions, and attention should be paid to correction risks